SMC Global Securities Limited

9️⃣ Are you planning to apply for the Anthem Biosciences IPO? Reply below with your thoughts If you found this breakdown useful, like, repost, and follow for more simplified IPO and market explainers #IPO #StockMarket #Pharma #Investing #IPO #StockMarket #Pharma #Investing

1️⃣ First, what’s the business model of Anthem Biosciences? It’s a Bengaluru-based CRDMO (Contract Research, Development, and Manufacturing Organization) They help pharma and biotech companies globally in drug discovery to manufacturing. They serve clients in 44+ countries https://t.co/0rnPr1wPGu

7️⃣ But what are the risks? • High dependency on CRDMO services • Revenue concentration in few clients • Supply chain disruptions may impact growth Always consider these before investing

5️⃣ How does Anthem compare with competitors? 🔹 RoE: 20.8% (highest) — Sai Life: 11%, Divi’s: 15.4% 🔹 P/E: 70.62 — below industry avg of 81.06 ⚡️ Anthem leads in efficiency & returns — yet remains undervalued

3️⃣But why is Anthem standing out? • 30% YoY revenue growth in FY25 (₹1,845 Cr) • 23% profit growth (₹451 Cr) • 32% EBITDA growth (₹684 Cr)

6️⃣ IPO Details: • Issue Size: ₹3,395 Cr • Price Band: ₹540–₹570 • Lot Size: 26 shares (₹14,820 Min Investment) • Issue Dates: July 14–16, 2025 • Listing: July 21, 2025

2️⃣But why is the market excited? The global CRDMO market is growing at 9% CAGR, driven by rising R&D spend and outsourcing. • Big pharma companies are outsourcing to save costs • India offers cost-effective, high-quality services India, with its cost advantage and quality https://t.co/ChxH8Xc0B9

💰 World's Wealth Titans in 2025 As of July 10, 2025, Nvidia has officially become the most valuable company in the world with a staggering $4.00 trillion market cap—riding the AI boom like never before. Here’s the updated leaderboard: NVIDIA – $4.00T Microsoft – $3.71T Apple – https://t.co/tI6jO4zb8i

4️⃣ Key strengths: • Works across small and large molecules • Pioneers in green and flow chemistry in India • Advanced tech use: RNAi, antibody-drug conjugates • 96.76% success rate with a client-centric fee-for-service model